A recent Survey of Ophthalmology review synthesized findings from cardiovascular outcomes trials, retrospective database analyses, meta-analyses and preclinical studies involving semaglutide, liraglutide, dulaglutide and related agents across six ocular conditions: diabetic retinopathy (DR), glaucoma, nonarteritic anterior ischemic optic neuropathy (NAION), age-related macular degeneration (AMD), idiopathic intracranial hypertension (IIH) and dry eye disease (DED)
In treated tendons, researchers observe formation of granulation tissue with active angiogenesis, increased reticulin fiber production, and organized collagen formation
Side effects you may experience with GLP-1s Like any medication, GLP-1 receptor agonists may cause side effects in some people
Individuals seeking steady energy and metabolic balance
Avoid intravenous (IV) administration unless explicitly directed by a medical professional